Imaging Extrastriatal Dopamine Release in Tobacco Smokers and Nonsmokers (NCT02348385) | Clinical Trial Compass
CompletedNot Applicable
Imaging Extrastriatal Dopamine Release in Tobacco Smokers and Nonsmokers
United States49 participantsStarted 2012-12
Plain-language summary
The goal is to examine sex differences in amphetamine-induced dopamine release in tobacco smokers and nonsmokers.
Who can participate
Age range18 Years – 55 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
General inclusion criteria:
* men and women, aged 18-55 years
* who are able to read and write
* who are able to give voluntary written informed consent
* have no current uncontrolled medical condition such as neurological, cardiovascular, endocrine, renal, liver, or thyroid pathology
* have no history of a neurological or psychiatric disorder, e.g., no DSM-IV Axis 1 diagnosis in 2 preceding years)
* drink less than 21 drinks/week for women and less than 35 drinks per week for men
* have not used marijuana in the past 30 days and have not met criteria for dependence in the past 2 years
* do not suffer from claustrophobia or any MRI contradictions
* to participate in imaging studies including 2 PET scans and 1 MRI scan
* nonsmokers (smoked \< 100 cigarettes in lifetime with urinary cotinine levels 0-30 ng/mL both at intake evaluation and on scan day)
* smokers (smoked at least 10 cigarettes/day for at least one year with an Fagerstrom score (FTND)\>3, urine cotinine \>150 ng/mL and carbon monoxide (CO) \>12 ppm at intake)
General exclusion criteria:
* psychosis
* presence of acute or unstable medical or neurological illness. Subjects will be excluded from the study if they present with any history of serious medical or neurological illness or if they show signs of a major medical or neurological illness on examination or lab testing including history of seizures, head injury, brain tumor, heart, liver or kidney disease, eating disorder, diabetes.
* regular use of any psycho…
What they're measuring
1
Percent Change in Binding Potential of Dopamine Release During PET Scan Post Amphetamine Administration